

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 58331

Manuscript Type: CASE REPORT

Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report

Yang CH *et al.* Multi-targets tyrosine kinase inhibitor and nephrotoxicity

Che Hseuh Yang, Kuo Tung Chen, Yi Sheng Lin, Chao Yu Hsu, Yen Chuan Ou, Min Che Tung

Match Overview

1

Crossref 12 words

Ankit Agrawal, Carlie Stein, Dan Hunt, Martin Rodriguez, Lisa L. Willett, Carlos Estrada. "Exercises in Clinical Reasoning: ...

<1%



Experiences of Successful Improvement of Nephrotic Syndrome by ✕



ALL

IMAGES

VIDEOS

1,470 Results

Any time ▼

[Nephrotic syndrome caused by the angiogenesis inhibitor ...](#)

https://www.researchgate.net/publication/38067357_Nephrotic_syndrome_caused_by_the...

Case presentation: We describe a patient with **metastatic thyroid cancer** who developed hypertension, **nephrotic syndrome**, and acute kidney injury after 3 months of **lenvatinib** treatment.

[\(PDF\) Management of regorafenib-related toxicities: A review](#)

https://www.researchgate.net/publication/276437653_Management_of_regorafenib-related...

Given the significant **improvement** in progression-free survival (PFS) of **sorafenib** compared to placebo demonstrated in the phase 3 DECISION trial, we **report** on a patient with **iodine-refractory** ...

[86th Annual Meeting of the American Thyroid Association ...](#)

<https://www.liebertpub.com/doi/full/10.1089/thy.2016.29022.abstracts>

Sep 01, 2016 · Nivolumab is currently approved for the treatment of melanoma, **metastatic** non-small cell lung **cancer**, and advanced renal cell **cancer**. We **report a case** of Nivolumab-induced **thyroid** dysfunction in a 58-year-old man with **metastatic** clear cell renal cell carcinoma. The patient had normal **thyroid** function tests (TFTs) prior to treatment with Nivolumab.

[\(PDF\) Acute blood pressure elevation associated with ...](#)

https://www.researchgate.net/publication/331882229_Acute_blood_pressure_elevation...

encephalopathy **syndrome** with concurrent **nephrotic syndrome** in a patient **treated** with pazopanib for **metastatic** renal cell carcinoma: **case report** and **review** of the literature.

[VEGF signalling inhibition-induced proteinuria: Mechanisms ...](#)

Improvement of lenvatinib-induced nephrotic syndrome after ada



ALL

IMAGES

VIDEOS

24,400 Results

Any time ▾

Focal segmental glomerulosclerosis lesion associated with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194623>

Oct 19, 2018 · This is the first report of renal histopathological findings associated with secondary FSGS due to a vascular endothelial disorder and podocyte damage induced by lenvatinib treatment. Nephrotic syndrome developed at approximately 3 months following initiation of lenvatinib treatment for **metastatic thyroid cancer in our patient**.

Cited by: 2

Author: Yoshitaka Furuto, Hirotsugu Hashimoto,...

Publish Year: 2018

Focal Segmental Glomerulosclerosis Lesion Associated With ...

<https://pubmed.ncbi.nlm.nih.gov/30340546>

Case presentation: We describe a patient with metastatic **thyroid cancer** who developed hypertension, **nephrotic syndrome**, and acute kidney injury **after** 3 months of lenvatinib treatment. Renal biopsy results revealed that 7 of 16 glomeruli indicated complete hyalinization, and that the glomeruli with incomplete hyalinization showed FSGS due to a ...

Cited by: 2

Author: Yoshitaka Furuto, Hirotsugu Hashimoto,...

Publish Year: 2018

Managing the adverse events associated with lenvatinib ...

<https://www.sciencedirect.com/science/article/pii/S0093775418302203>

Feb 01, 2019 · Lenvatinib-induced thrombocytopenia may be caused by the **suppression of hematopoiesis** due to the **inhibition of PDGFR**, a known target of lenvatinib , , , . Throughout the course of treatment, complete blood counts should be routinely monitored for evidence of thrombocytopenia , .

Cited by: 6

Author: Maria E. Cabanillas, Shunji Takahashi

Publish Year: 2019

Focal segmental glomerulosclerosis lesion associated with ...



29,000 Results

Any time ▼

[Focal Segmental Glomerulosclerosis Lesion Associated With ...](#)

<https://pubmed.ncbi.nlm.nih.gov/30340546>

Case presentation: We describe a patient with metastatic **thyroid cancer** who developed hypertension, **nephrotic syndrome**, and acute kidney injury **after** 3 months of lenvatinib treatment. Renal biopsy results revealed that 7 of 16 glomeruli indicated complete hyalinization, and that the glomeruli with incomplete hyalinization showed FSGS due to a ...

Cited by: 2**Author:** Yoshitaka Furuto, Hirotsugu Hashimoto, ...**Publish Year:** 2018

[Managing the adverse events associated with lenvatinib ...](#)

<https://www.sciencedirect.com/science/article/pii/S0093775418302203>

Feb 01, 2019 · Differentiated **thyroid cancer** (DTC) is the most common type of **thyroid cancer** in the United States, making up over 90% of all **thyroid** carcinoma cases , . For most patients diagnosed with DTC, standard treatment is surgery followed by administration of radioactive iodine [3] , [4] .

Cited by: 6**Author:** Maria E. Cabanillas, Shunji Takahashi**Publish Year:** 2019

[Posterior reversible encephalopathy syndrome and takotsubo ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021337>

Jun 15, 2018 · Posterior reversible encephalopathy **syndrome** and takotsubo cardiomyopathy associated with lenvatinib therapy for **thyroid cancer: a case report** and review Young Kwang Chae , # 1, 2 Lauren Chiec , # 1 Scott K. Adney , 1 Josh Waitzman , 1 Ricardo Costa , 3 Benedito Carneiro , 4 Maria Matsangou , 1, 2 Mark Agulnik , 1, 2 Peter Kopp , 1 and Frank ...

Cited by: 2**Author:** Young Kwang Chae, Lauren Chiec, Scott ...**Publish Year:** 2018

[Focal segmental glomerulosclerosis lesion associated with ...](#)

<https://europepmc.org/article/MED/30340546> ▼

Oct 19, 2018 · In conclusion, we **report**, for the first time, **a case of lenvatinib-induced** FSGS that resulted in irreversible renal damage. Lenvatinib is an antineoplastic agent used to treat **thyroid cancer** due to its inhibitory effects on several tyrosine kinases involved in tumor vascularization and growth.

Cited by: 2**Author:** Yoshitaka Furuto, Hirotsugu Hashimoto, ...**Publish Year:** 2018